Observation on the Efficacy of Radiofrequency Ablation for Patients With Moderate to Severe Gastric Atrophy With Enterosis With or Without Atrophy of Intraepithelial Neoplasia: An Observational Study

Launched by XIULI ZUO · Dec 26, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a treatment called radiofrequency ablation is for patients with moderate to severe gastric atrophy and enterosis, with or without a condition known as low-grade intraepithelial neoplasia (a type of abnormal cell growth). The main goal is to see if this treatment can help reduce the damage in the stomach lining and improve the overall condition in these patients.

To be eligible for this study, participants need to be between 18 and 70 years old and have been diagnosed with a specific type of chronic gastritis that is moderately to severely atrophic. They also need to have had a gastroscopy (a procedure to look inside the stomach) within the last three months and must test negative for Helicobacter pylori, a bacteria that can cause stomach issues. Participants can expect to be part of an observational study, meaning they will be monitored to see how the treatment affects their condition, but they won’t be randomly assigned to different treatments. It's important to note that pregnant or breastfeeding women, those with certain medical conditions, or anyone unable to give consent will not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-70 years old, male or female.
• • Patients who had undergone gastroscopy within 3 months prior to inclusion, and whose histologic diagnosis of chronic gastritis was histologically atrophic enterocolitis graded at moderate-to-severe with or without low-grade intraepithelial neoplasia.
• • Patients who had undergone gastroscopy within 3 months prior to inclusion, and whose OLGA (atrophic grading and staging criteria for chronic gastritis) or OLGIM (enteric grading and staging criteria for chronic gastritis) staging criteria had reached moderately severe.
• • Helicobacter pylori negative.
• Exclusion Criteria:
• • Pregnant or lactating women.
• • Previous history of malignant tumors of the digestive tract or history of gastrointestinal surgery.
• • Malignant tumors of other organs, coagulation disorders, cardiopulmonary insufficiency, hepatic and renal insufficiency, etc.
• • Those who are unable or unwilling to sign the informed consent form.